Cargando…

Clinical Response to Valproate in Patients with Migraine

BACKGROUND AND PURPOSE: Valproate is used as a prophylactic drug for migraine, but it is not be effective in all patients. We used medical records to investigate which clinical factors affected the response to valproate in patients with migraine as an original headache, and established a scoring sys...

Descripción completa

Detalles Bibliográficos
Autores principales: Ichikawa, Mizuki, Katoh, Hirotaka, Kurihara, Tatsuya, Ishii, Masakazu
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Korean Neurological Association 2016
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5063874/
https://www.ncbi.nlm.nih.gov/pubmed/27819417
http://dx.doi.org/10.3988/jcn.2016.12.4.468
_version_ 1782460051511836672
author Ichikawa, Mizuki
Katoh, Hirotaka
Kurihara, Tatsuya
Ishii, Masakazu
author_facet Ichikawa, Mizuki
Katoh, Hirotaka
Kurihara, Tatsuya
Ishii, Masakazu
author_sort Ichikawa, Mizuki
collection PubMed
description BACKGROUND AND PURPOSE: Valproate is used as a prophylactic drug for migraine, but it is not be effective in all patients. We used medical records to investigate which clinical factors affected the response to valproate in patients with migraine as an original headache, and established a scoring system for predicting the clinical response to prophylactic therapy. METHODS: We investigated clinical factors from the medical records of 95 consistent responders (CRs) and 24 inconsistent responders (IRs) to valproate. RESULTS: Multivariate stepwise logistic regression analysis revealed that a history of hyperlipidemia and hay fever and the complication of depression or other psychiatric disorder were significant factors that independently contributed to a negative response, with odds ratios of 6.024 [no vs. yes; 95% confidence interval (CI)=1.616–22.222], 2.825 (no vs. yes; 95% CI=1.046–7.634), and 2.825 (no vs. yes; 95% CI=1.052–7.576), respectively. A predictive index (PI) of the clinical response to valproate in patients with migraine was calculated using the regression coefficients of these three factors as an integer, and the index was significantly higher for IRs than for CRs (1.46±1.10 vs. 0.69±0.74, mean±SD, p<0.001). CONCLUSIONS: The obtained PI may represent an appropriate scoring system for predicting the responses in these patients.
format Online
Article
Text
id pubmed-5063874
institution National Center for Biotechnology Information
language English
publishDate 2016
publisher Korean Neurological Association
record_format MEDLINE/PubMed
spelling pubmed-50638742016-10-17 Clinical Response to Valproate in Patients with Migraine Ichikawa, Mizuki Katoh, Hirotaka Kurihara, Tatsuya Ishii, Masakazu J Clin Neurol Original Article BACKGROUND AND PURPOSE: Valproate is used as a prophylactic drug for migraine, but it is not be effective in all patients. We used medical records to investigate which clinical factors affected the response to valproate in patients with migraine as an original headache, and established a scoring system for predicting the clinical response to prophylactic therapy. METHODS: We investigated clinical factors from the medical records of 95 consistent responders (CRs) and 24 inconsistent responders (IRs) to valproate. RESULTS: Multivariate stepwise logistic regression analysis revealed that a history of hyperlipidemia and hay fever and the complication of depression or other psychiatric disorder were significant factors that independently contributed to a negative response, with odds ratios of 6.024 [no vs. yes; 95% confidence interval (CI)=1.616–22.222], 2.825 (no vs. yes; 95% CI=1.046–7.634), and 2.825 (no vs. yes; 95% CI=1.052–7.576), respectively. A predictive index (PI) of the clinical response to valproate in patients with migraine was calculated using the regression coefficients of these three factors as an integer, and the index was significantly higher for IRs than for CRs (1.46±1.10 vs. 0.69±0.74, mean±SD, p<0.001). CONCLUSIONS: The obtained PI may represent an appropriate scoring system for predicting the responses in these patients. Korean Neurological Association 2016-10 2016-09-30 /pmc/articles/PMC5063874/ /pubmed/27819417 http://dx.doi.org/10.3988/jcn.2016.12.4.468 Text en Copyright © 2016 Korean Neurological Association http://creativecommons.org/licenses/by-nc/3.0/ This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (http://creativecommons.org/licenses/by-nc/3.0/) which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited.
spellingShingle Original Article
Ichikawa, Mizuki
Katoh, Hirotaka
Kurihara, Tatsuya
Ishii, Masakazu
Clinical Response to Valproate in Patients with Migraine
title Clinical Response to Valproate in Patients with Migraine
title_full Clinical Response to Valproate in Patients with Migraine
title_fullStr Clinical Response to Valproate in Patients with Migraine
title_full_unstemmed Clinical Response to Valproate in Patients with Migraine
title_short Clinical Response to Valproate in Patients with Migraine
title_sort clinical response to valproate in patients with migraine
topic Original Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5063874/
https://www.ncbi.nlm.nih.gov/pubmed/27819417
http://dx.doi.org/10.3988/jcn.2016.12.4.468
work_keys_str_mv AT ichikawamizuki clinicalresponsetovalproateinpatientswithmigraine
AT katohhirotaka clinicalresponsetovalproateinpatientswithmigraine
AT kuriharatatsuya clinicalresponsetovalproateinpatientswithmigraine
AT ishiimasakazu clinicalresponsetovalproateinpatientswithmigraine